BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28835680)

  • 21. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.
    Pham T; Landewé R; van der Linden S; Dougados M; Sieper J; Braun J; Davis J; Rudwaleit M; Collantes E; Burgos-Vargas R; Edmonds J; Olivieri I; van der Horst-Bruinsma I; Mielants H; Stone M; Emery P; van der Heijde D
    Ann Rheum Dis; 2006 Dec; 65(12):1620-5. PubMed ID: 16464984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis.
    Lee JW; Kang JH; Yim YR; Kim JE; Wen L; Lee KE; Park DJ; Kim TJ; Park YW; Lee SS
    PLoS One; 2015; 10(7):e0131864. PubMed ID: 26176701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; González-Juanatey C; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2014; 32(2):218-24. PubMed ID: 24351434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-TNF Therapy Regulates Phagosome Pathway by Inhibiting NCF4 Expression to Treat Ankylosing Spondylitis.
    Liu S; Zhu H
    J Musculoskelet Neuronal Interact; 2023 Sep; 23(3):355-364. PubMed ID: 37654221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis.
    van Sijl AM; van Eijk IC; Peters MJ; Serné EH; van der Horst-Bruinsma IE; Smulders YM; Nurmohamed MT
    Ann Rheum Dis; 2015 Jan; 74(1):119-23. PubMed ID: 24092419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research.
    Kim HW; Kwon SR; Jung KH; Kim SK; Baek HJ; Seo MR; Bang SY; Lee HS; Suh CH; Jung JY; Son CN; Shim SC; Lee SH; Lee SG; Lee YA; Lee EY; Kim TH; Kim YG;
    PLoS One; 2016; 11(4):e0153816. PubMed ID: 27101309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular cytokine patterns in Behçet's disease in comparison to ankylosing spondylitis--influence of treatment with interferon-alpha2a.
    Amberger M; Groll S; Günaydin I; Deuter C; Vonthein R; Kötter I
    Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S52-7. PubMed ID: 17949552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of genes encoding cytokines (IL6, IL10, TNF), cytokine receptors (IL6R, IL6ST), and glucocorticoid receptor (NR3C1) and susceptibility to bronchopulmonary dysplasia.
    Huusko JM; Karjalainen MK; Mahlman M; Haataja R; Kari MA; Andersson S; Toldi G; Tammela O; Rämet M; Lavoie PM; Hallman M;
    BMC Med Genet; 2014 Nov; 15():120. PubMed ID: 25409741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
    Korkosz M; Gąsowski J; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
    Scand J Rheumatol; 2014; 43(1):43-8. PubMed ID: 24447112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Arias-Bajo M; Rueda-Gotor J; Paz-Carreira J; González-Juanatey C; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2014; 32(2):231-6. PubMed ID: 24295386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of Notch1/Hes signaling pathway in ankylosing spondylitis.
    Xu W; Liang CG; Li YF; Ji YH; Qiu WJ; Tang XZ
    Int J Clin Exp Pathol; 2015; 8(3):2737-45. PubMed ID: 26045779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
    Nell-Duxneuner V; Schroeder Y; Reichardt B; Bucsics A
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.
    Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Mijares V; Carnero-López B; Gómez-Acebo I; Dierssen-Sotos T; Remuzgo-Martínez S; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
    Rheumatol Int; 2015 Dec; 35(12):2069-78. PubMed ID: 26143161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2013; 31(4):532-7. PubMed ID: 23484462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.
    Duftner C; Dejaco C; Kullich W; Klauser A; Goldberger C; Falkenbach A; Schirmer M
    Ann Rheum Dis; 2006 May; 65(5):647-53. PubMed ID: 16219708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
    Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
    Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.
    Heinonen AV; Aaltonen KJ; Joensuu JT; Lähteenmäki JP; Pertovaara MI; Romu MK; Hirvonen HE; Similä AK; Blom ML; Nordström DC
    J Rheumatol; 2015 Dec; 42(12):2339-46. PubMed ID: 26472421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in gene expression profiles of the hip joint ligament of patients with ankylosing spondylitis revealed by DNA chip.
    Xu L; Sun Q; Jiang S; Li J; He C; Xu W
    Clin Rheumatol; 2012 Oct; 31(10):1479-91. PubMed ID: 22903699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.